BlinkLab Targeting Opportunities Beyond Flagship Autism Program

MT Newswires Live

07/14

BlinkLab (ASX:BB1) is expanding its study portfolio to evaluate its smartphone-based neurometric platform across additional neurological and psychiatric conditions beyond the company's flagship autism diagnostic program, according to a Tuesday filing with the Australian bourse.

The company said it has 10 ongoing clinical development programs aimed at validating new applications, establishing research collaborations, and identifying new commercial opportunities. These include a program for pediatric attention-deficit/hyperactivity disorder, early dementia detection, and spinocerebellar ataxia.

BlinkLab expects to deliver readouts from five programs this year, followed by five additional readouts in 2027, per the filing.

The company is also targeting a US Food and Drug Administration submission for its BlinkLab Dx1 diagnostic product by the end of the year.

BlinkLab's shares fell past 2% in recent Tuesday trade.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2651129040"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2651129040\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2651129040?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-14 12:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651129040","market":"sh","top_or_hot":-1,"title":"BlinkLab Targeting Opportunities Beyond Flagship Autism Program","media":"MT Newswires Live","content":"<html><body><p> BlinkLab (ASX:BB1) is expanding its study portfolio to evaluate its smartphone-based neurometric platform across additional neurological and psychiatric conditions beyond the company's flagship autism diagnostic program, according to a Tuesday filing with the Australian bourse.</p><p>The company said it has 10 ongoing clinical development programs aimed at validating new applications, establishing research collaborations, and identifying new commercial opportunities. These include a program for pediatric attention-deficit/hyperactivity disorder, early dementia detection, and spinocerebellar ataxia.</p><p>BlinkLab expects to deliver readouts from five programs this year, followed by five additional readouts in 2027, per the filing.</p><p>The company is also targeting a US Food and Drug Administration submission for its BlinkLab Dx1 diagnostic product by the end of the year.</p><p>BlinkLab's shares fell past 2% in recent Tuesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BlinkLab Targeting Opportunities Beyond Flagship Autism Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBlinkLab Targeting Opportunities Beyond Flagship Autism Program\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-07-14 12:35</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> BlinkLab (ASX:BB1) is expanding its study portfolio to evaluate its smartphone-based neurometric platform across additional neurological and psychiatric conditions beyond the company's flagship autism diagnostic program, according to a Tuesday filing with the Australian bourse.</p><p>The company said it has 10 ongoing clinical development programs aimed at validating new applications, establishing research collaborations, and identifying new commercial opportunities. These include a program for pediatric attention-deficit/hyperactivity disorder, early dementia detection, and spinocerebellar ataxia.</p><p>BlinkLab expects to deliver readouts from five programs this year, followed by five additional readouts in 2027, per the filing.</p><p>The company is also targeting a US Food and Drug Administration submission for its BlinkLab Dx1 diagnostic product by the end of the year.</p><p>BlinkLab's shares fell past 2% in recent Tuesday trade.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7094","symbol_name":"醫療保健技術","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2651129040","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651129040","pubTimestamp":1784003738,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BlinkLab (ASX:BB1) is expanding its study portfolio to evaluate its smartphone-based neurometric platform across additional neurological and psychiatric conditions beyond the company's flagship autism","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7094":"医疗保健技术","BB1.AU":"Blinklab Ltd"},"translate_title":"BlinkLab 瞄准自闭症旗舰项目之外的机会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BB1.AU":1},"content_text":"BlinkLab (ASX:BB1) is expanding its study portfolio to evaluate its smartphone-based neurometric platform across additional neurological and psychiatric conditions beyond the company's flagship autism diagnostic program, according to a Tuesday filing with the Australian bourse.The company said it has 10 ongoing clinical development programs aimed at validating new applications, establishing research collaborations, and identifying new commercial opportunities. These include a program for pediatric attention-deficit/hyperactivity disorder, early dementia detection, and spinocerebellar ataxia.BlinkLab expects to deliver readouts from five programs this year, followed by five additional readouts in 2027, per the filing.The company is also targeting a US Food and Drug Administration submission for its BlinkLab Dx1 diagnostic product by the end of the year.BlinkLab's shares fell past 2% in recent Tuesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}